Literature DB >> 4947213

Meningococcal infections. 5. Duration of polysaccharide-vaccine-induced antibody.

M S Artenstein.   

Abstract

Serum antibodies induced in 12 volunteer subjects by injection of group A and group C meningococcal polysaccharide vaccines were found to persist for periods exceeding 14 months. Antibody response was measured by indirect haemagglutination and fluorescent antibody assays. Peak titres were reached in 2-8 weeks.

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4947213      PMCID： PMC2427925     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN： 0042-9686            Impact factor:   9.408


  7 in total

1.  Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man.

Authors:  M S Artenstein; R Gold; J G Zimmerly; F A Wyle; W C Branche; C Harkins
Journal:  J Infect Dis       Date:  1970-04       Impact factor: 5.226

2.  The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man.

Authors:  R B Roberts
Journal:  J Exp Med       Date:  1970-03-01       Impact factor: 14.307

3.  Human immunity to the meningococcus. II. Development of natural immunity.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

4.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

5.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

6.  ANTIBODY FORMATION IN VOLUNTEERS FOLLOWING INJECTION OF PNEUMOCOCCI OR THEIR TYPE-SPECIFIC POLYSACCHARIDES.

Authors:  M Heidelberger; C M Macleod; S J Kaiser; B Robinson
Journal:  J Exp Med       Date:  1946-03-31       Impact factor: 14.307

7.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307
  7 in total
  8 in total

Review 1.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 2.  Diagnosis and management of bacterial meningitis.

Authors:  G Hambleton; P A Davies
Journal:  Drugs       Date:  1974       Impact factor: 9.546

3.  Three cases of meningococcal infection in a family, associated with a deficient immune response.

Authors:  D M Jones; B M Tobin; A Butterworth
Journal:  Arch Dis Child       Date:  1973-09       Impact factor: 3.791

4.  Incidence of haemagglutinating antibodies to meningococci in north-west England.

Authors:  D M Jones; B M Tobin
Journal:  J Clin Pathol       Date:  1972-11       Impact factor: 3.411

5.  Duration of the immune response in subjects inoculated with antimeningococcal A and C vaccines kept in storage at -20 degrees C and at 4 degrees C: influence of pre-vaccination titres on the vaccinal response.

Authors:  S Grinstein; T M Kahn; S Tisminetsky; M Donadio; G Weyland
Journal:  J Hyg (Lond)       Date:  1981-02

6.  Activation of murine B lymphocytes by Neisseria meningitidis and isolated meningococcal surface antigens.

Authors:  J Melancon; R A Murgita; I W Devoe
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

7.  Antibody responses to meningococcal polysaccharide vaccines.

Authors:  B L Brandt; M S Artenstein; C D Smith
Journal:  Infect Immun       Date:  1973-10       Impact factor: 3.441

8.  Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.

Authors:  Daniel Holme; Helen Findlow; Samba O Sow; Olubukola T Idoko; Marie-Pierre Preziosi; George Carlone; Brian D Plikaytis; Ray Borrow
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.